Advances in whole-genome sequencing (WGS) and artificial intelligence are reshaping how oncology clinical trials detect and monitor cancer.

In this webinar, Phil Febbo, Chief Scientific and Medical Officer at Veracyte, introduces Veracyte’s TrueMRD platform and its utility in tumor-informed circulating tumor DNA (ctDNA) analysis for monitoring minimal residual disease (MRD), treatment response, and clonal evolution. 

Get insights into how WGS-based ctDNA profiling enables earlier detection, sensitive MRD monitoring, deeper whole-genome insights, and more personalized drug development and patient management. Dr. Febbo discusses studies that illustrate how the TrueMRD platform delivers high sensitivity from minimal input volume, unlocking new opportunities in trial design, clinical decision support, and biomarker development.

Key Takeaways 

• How whole-genome analysis of plasma ctDNA fragments provides deeper insights into patient therapy sensitivity and resistance for more personalized drug development and patient management
• The role of AI-driven, whole-genome based patient-specific signatures
• Applications in treatment monitoring and post-therapy tumor evolution and tracking 
• Advantages of minimal input volumes and rapid turnaround times for WGS-based MRD results
• Opportunities for pharma collaboration, biomarker discovery, and clinical trial integration 

Questions about the Veracyte TrueMRD platform?

Please contact [email protected]